BioCryst Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BioCryst Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 213.2 times by its yearly operating cash. Higher than almost all Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 34.8 times. Higher than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
34.8×Over the last 3 years its own operating cash covered its investment spending (capex) 34.8 times.
Higher than 98% of Healthcare companies in United States.
Cash Locked Ratio
$10For every $100 of sales, $10 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $21 tied up three years earlier.
Less money tied up than 80% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$85Sales grew 223% in 3 years; of every extra $100 of sales, $85 became extra profit.
Higher than 79% of Healthcare companies in United States.
Asset Productivity Ratio
+223% / -7%In 3 years sales changed by +223% while total assets changed by -7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
213.2×Debt due within a year is covered 213.2 times by its yearly operating cash.
Higher than almost all Healthcare companies in United States.
Cash Cushion Ratio
−8%Debt, after subtracting cash, equals 8% of its market value (net debt).
Lower than 77% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
BioCryst Pharmaceuticals, Inc. made a loss over the last year. BioCryst Pharmaceuticals, Inc. owes $1.81 for every $1 it owns. BioCryst Pharmaceuticals, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBioCryst Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-4.38BioCryst Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$2.0 BThe total market value of all of BioCryst Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeBioCryst Pharmaceuticals, Inc.'s net worth is negative ($454 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.81×BioCryst Pharmaceuticals, Inc. owes $1.81 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Dividend yield
NoneBioCryst Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+94%Revenue rose 94% in the year to Dec 2025, and grew 48% a year on average over 3 years.
Profit growth
Back to profitBioCryst Pharmaceuticals, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
30.2%BioCryst Pharmaceuticals, Inc. keeps $30 of every $100 of revenue as net profit.
Cash quality
1.3×Cash from BioCryst Pharmaceuticals, Inc.'s business was 1.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
4.3×BioCryst Pharmaceuticals, Inc.'s operating profit covered its interest costs 4.3 times in the year to Dec 2025.
Cash vs debt
Net debtBioCryst Pharmaceuticals, Inc. had $164 M more debt than cash (net debt) at Dec 2025.
Questions
How much does BioCryst Pharmaceuticals, Inc. owe compared with what it owns?
BioCryst Pharmaceuticals, Inc. owes $1.81 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Does BioCryst Pharmaceuticals, Inc. pay a dividend?
No. BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.
Is BioCryst Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 94% in the year to Dec 2025, and grew 48% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.